Picked from the four briefs' latest editions

Your Intelligence Brief

8 items · about 10 min

Adjust

Each brief's top stories, in the order its editors printed them, one brief at a time.

Human-led · Source-checked

Biotech & Pharma · No. 052 · Must read Co Reg

Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients

Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients at 32 mg, its chosen dose. The Phase 1 trial has no control group, and response rate is a secondary endpoint. Single-arm, early and company-reported, so it cannot show benefit over other treatment. Erasca plans a first-line pancreatic Phase 3 in the first half of 2027.

Biotech & Pharma's story 01 today, marked Must read.

Five things to know · about 2 min

AI & Technology · No. 052 · Must read Data Press

The S&P 500 closes in correction as chip stocks fall about 10%

The S&P 500 closes in correction. The S&P 500 fell 3.70% to 6,910.39, 11.62% below its 10.06 record close. The Nasdaq 100 fell 5.61% and the VIX closed at 35.89. The selling was heaviest in chips and memory, the companies closest to AI spending. Consumer staples and health care rose, per Reuters.

AI & Technology's story 01 today, marked Must read.

Five things to know · about 2 min

Life · No. 002 · Know it Verified Analysis

Why beef costs more this year

Life's story 01 today, marked Know it.

Signal · about 1 min

Biotech & Pharma · No. 052 · Must read Co Reg

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months. Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.

Biotech & Pharma's story 02 today, marked Must read.

Five things to know · about 1 min

AI & Technology · No. 052 · Must read Co Data

Anthropic closes its IPO at about $119.5 billion combined; the stock falls 8.98%

Anthropic closes its IPO; the stock falls 8.98%. Anthropic says gross proceeds were about $93.5 billion from the offering and about $26.0 billion from a private placement. ANT’s last regular-session trade was $88.445. The stock is still above its $83 offer price. Some analysts say the deal may have pulled money from other tech; we found no fund-flow data showing it.

AI & Technology's story 02 today, marked Must read.

Five things to know · about 1 min

Biotech & Pharma · No. 052 · Must read Co Reg

Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint

Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65. The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof.

Biotech & Pharma's story 03 today, marked Must read.

Five things to know · about 1 min

Life · No. 002 ·

Life's lead · chosen by Life's editors

The cookie that ran on wood ash

Not picked by your settings. Optional, about 31 min for the whole edition.

Not on screen yet: Worldview No. 011 (PDF available).

That's your brief for today.

8 items, about 10 min. Nothing here is rewritten: every item is the edition's own story and short line, with its brief, date and labels.

Full Context: developing stories · Public calls and how they turned out

Each brief in full:

Scroll less. Know more.

Four intelligence briefs covering biotech, AI and technology, global affairs and life. Key claims linked to sources, counterarguments made explicit, forecasts tracked publicly, and corrections recorded.

Join Mind Club (punitdhillon.com, opens in a new tab) Sign in

It’s complimentary. Coverage, formats and features may change.

Explore each brief

The record

Every call is graded in public and every correction is logged with the date, on each brief's track record page.